Frontlight ResearchEarly access
Alzheimer disease trials in Peru
2 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3WithdrawnOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
- Where
- Callao, Miraflores
- Age
- 55 years to 90 years
- People
- 1,000 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05980949 · EU 2023-504151-27-00 - Phase 3WithdrawnA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
- Where
- Callao, Miraflores, Pueblo Libre
- Age
- 55 years to 90 years
- People
- 500 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06126224 · EU 2023-504416-16-00